Recent Press Releases

Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

WALTHAM, Mass.--Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive...

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the inauguration of its new R&D center, Ipsen Bioscience, in Cambridge (MA, USA), a recognized hub in the USA for biomedical research &...

Calico Licenses Technology from Acclaimed UCSF Laboratory

Calico, a company whose mission is to harness advanced technologies to increase understanding of the biology that controls human lifespan, and UC San Francisco have partnered on an innovative project...

De Blasio Administration Launches Major Funding Initiative to Create Thousands of Jobs in City's Life Sciences Sector

Leading Life Sciences Venture Capital Firms to Manage $150 Million Public-Private Partnership and Establish Presence in NYC, Bolstering City as a Global Industry Leader Commitment to Expand Current...

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT PledPharma AB (publ) today announces top-line...

aTyr Pharma Secures $76 Million in Series E Financing

aTyr Pharma Secures $76 Million in Series E Financing Published: Mar 31, 2015 5:15 p.m. ET – Proceeds to Support Physiocrine-Based Clinical Development Program and Pipeline Expansion –...

Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs

– Christopher Garabedian Resigns as Chief Executive Officer and Member of the Board Effective Today –– Company will host conference call at 8:00 a.m. EDT, April 1, 2015 –...

Experimental cancer drug restores memory in mouse model of Alzheimer's

Star–like glial cells in red surround alpha beta plaques in the cortex of a mouse with a model of Alzheimer's Disease. Memory and as well as connections between brain cells were restored in...

PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services

BOSTON -- PAREXEL International Corporation (Nasdaq: PRXL), a global clinical research organization, announced today that the Company has signed a definitive agreement to acquire all of the business...

GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome London, UK, 31 March 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the...

Cerulean Announces Proposed Public Offering of Common Stock

Cerulean Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (Nasdaq: CERU) today announced that it has commenced an underwritten public...

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services Combines the complementary strengths and scale of leading biopharmaceutical services and...

Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease

Cambridge, Mass. March 31st, 2015 — The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The...

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma WALTHAM, Mass. & KENILWORTH,...

Fujifilm Holdings to Acquire Cellular Dynamics International, Inc.

TOKYO and MADISON, Wis., March 30, 2015 /PRNewswire/ -- FUJIFILM Holdings Corporation (President: Shigehiro Nakajima,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, Inc....

Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital

CAMBRIDGE, Mass. -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating...

The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) and RAPLIXA™ (sealant powder)

Marketing authorization valid in 31 countries of the European Economic Area -- KENGREXAL™ is the first and only intravenous antiplatelet agent that provides immediate, consistent, and rapidly...

Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab

ZUG, Switzerland--Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade®1 as the reference product, has...

Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis

PETACH TIKVA, Israel, March 30, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and...

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development

RALEIGH, N.C., March 30, 2015 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared...